TNFSF10 and colorectal carcinoma: Regarding rafoxanide, we recently showed that the drug acts as a selective TNF-related apoptosis-inducing ligand (TRAIL) sensitizer in vitro and in a syngeneic experimental model of CRC, by decreasing levels of c-FLIP and survivin [69], two key molecules conferring resistance to TRAIL [70].